$2.07+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Just reported
From Foghorn Therapeutics Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Actual
$83.5M
Guided
—
No guide given
Actual
$0.80
Guided
—
No guide given
Actual
$56.6M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $83.5M | $8.2M | +924.69% |
| Profit | $58.2M | -$15.8M | +466.90% |
| Profit per share | $0.80 | -$0.25 | +420.00% |
| Free Cash Flow | -$18.3M | -$18.9M | +3.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Foghorn Therapeutics Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Therapeutics Foghorn® Therapeutics is a biotechnology company developing novel medicines against challenging biological targets through multiple modalities and approaches, including oral small molecules, targeted protein degradation, and induced proximity. The Company is advancing programs in oncology as well as immunology and inflammation. Foghorn brings together deep biological understanding and small-molecule drug discovery expertise to pursue challenging targets with selectivity. Visit our website at www.foghorntx.com
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Foghorn Therapeutics Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.